(VXRT) – Press Releases
-
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3
-
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Vaxart Provides Business Update and Reports Full Year 2023 Financial Results
-
Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14
-
Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director
-
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding
-
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
-
Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management
-
Vaxart, Inc. Announces Management Change
-
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
-
Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results
-
Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
-
Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2
-
Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19
-
Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference
-
Vaxart Announces Topline Data from the Phase 2 Challenge Study of its Monovalent Norovirus Vaccine Candidate
-
Vaxart Provides Business Update and Reports Second Quarter 2023 Financial Results
-
Vaxart to Host Second Quarter 2023 Business Update and Financial Results Conference Call on August 3
-
Vaxart Announces Positive Preliminary Topline Data from Dose-Ranging Phase 2 Study of its Bivalent Norovirus Vaccine Candidate
-
Vaxart Stockholders Approve All Four Proposals in the 2023 Proxy Statement
-
Vaxart Encourages All Stockholders of Record as of April 28, 2023 to Vote by June 25, 2023, at 11:59 p.m. ET
-
Vaxart, Inc. Announces Pricing of $15,000,000 Public Offering of Common Stock
-
Vaxart, Inc. Announces Proposed Public Offering of Common Stock
-
Vaxart Announces Last Subject Dosed in Phase 2 Trial of its Bivalent Norovirus Candidate, and All Subjects Challenged in Phase 2 Challenge Study of Monovalent Norovirus Candidate
-
Vaxart Launches New Investor Communication Program, First Event Scheduled for June 15 at 11 a.m. ET
-
Vaxart Provides Business Update and Reports First Quarter 2023 Financial Results
-
Vaxart to Host First Quarter 2023 Business Update and Financial Results Conference Call on May 4
-
Vaxart to Present at World Vaccine Congress Washington 2023 on April 5-6
-
Vaxart to Host Webcast with Key Opinion Leaders to Discuss the Health Impact and Disease Burden for Norovirus
-
Vaxart Provides Business Update and Full Year 2022 Financial Results
-
Vaxart to Host Full Year 2022 Business Update and Financial Results Conference Call on March 15
-
Vaxart Doses First Subject in the Phase 2 Clinical Trial of its Bivalent Norovirus Candidate
-
Vaxart Names Phillip Lee as Chief Financial Officer
-
Vaxart Announces Collaborative Funding from Leading Foundation to Study Its Norovirus Vaccine Candidate in Breastfeeding Mothers
-
Vaxart to Present at World Vaccine & Immunotherapy Congress West Coast 2022 on November 29
-
Vaxart Provides Business Update and Reports Third Quarter 2022 Financial Results
-
Vaxart to Host Third Quarter 2022 Business Update and Financial Results Conference Call on November 8
-
Vaxart to Present at World Vaccine Congress Europe 2022 on October 13
-
Vaxart to Present at the H.C. Wainwright 24th Annual Global Investment Conference
-
Vaxart Announces Positive Top-line Phase II Clinical Study Data Demonstrating Safety and Immunogenicity of Its Wuhan S-Only COVID-19 Pill Vaccine Candidate
-
Vaxart to Host Conference Call on September 1 at 8:30 AM ET to Discuss Top-line Results from Its Phase II COVID-19 Trial
-
Vaxart Names Biotech Veteran Ray Stapleton Chief Technology Officer
-
Vaxart Announces Highly Regarded Biotech Executive Elaine J. Heron, Ph.D. Joins Board of Directors
-
Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results
-
Vaxart Appoints W. Mark Watson to its Board of Directors
-
Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4
-
Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8
-
Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET
-
Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET
-
Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive
Back to VXRT Stock Lookup
